Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34476313 | 1.00 | CYP4F2 (0.49) | CYP4F2CYP4A11NPSR1MEN1KMT2A | |
| SCHEMBL25188768 | 0.98 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1MEN1KMT2A | |
| SCHEMBL31369186 | 0.84 | CYP4F2 (0.38) | CYP4F2CYP4A11NPSR1MEN1KMT2A | |
| SCHEMBL2633876 | 0.83 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1MEN1KMT2A | |
| SCHEMBL2472218 | 0.82 | CYP2C19 (0.36) | CYP4F2CYP4A11NPSR1MEN1KMT2A | |
| SCHEMBL34475482 | 0.82 | CYP4F2 (0.39) | CYP4F2CYP4A11NPSR1 | |
| SCHEMBL1273304 | 0.82 | OPRM1 (0.36) | CYP4F2CYP4A11NPSR1KMT2A | |
| SCHEMBL31369221 | 0.82 | CYP4F2 (0.36) | CYP4F2CYP4A11NPSR1LMNA | |
| SCHEMBL9797061 | 0.82 | MEN1 (0.40) | NPSR1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL15237366 | 0.81 | CYP4F2 (0.35) | CYP4F2CYP4A11NPSR1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090509-A1 | SPIRO HETEROCYCLIC CDK2 INHIBITORS | ARCHITECT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| CN-116333531-A | Colorant dispersions, inks, ink sets, and prints | 东洋油墨SC控股株式会社 | 2023-06-27 | — | — | CN | disclosed |
| US-9533995-B2 | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof | SANOFI (FR) | 2017-01-03 | — | — | US | disclosed |
| US-9533995-B2 | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof | SANOFI (FR) | 2017-01-03 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2569280-B1 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| EP-2569280-B1 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-23 | — | — | US | disclosed |
| US-20080194826-A1 | Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. | 2008-08-14 | — | — | US | disclosed |
| US-7375115-B2 | 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375115-B2 | 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20080058365-A1 | Fused heterocyclic compounds | AMGEN INC. | 2008-03-06 | — | — | US | disclosed |
| US-7253179-B2 | Fused heterocyclic compounds | AMGEN INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1562943-A1 | FUSED HETEROCYCLIC COMPOUNDS | Amgen Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050085508-A1 | Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1443046-A1 | NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-08-04 | — | — | EP | disclosed |
| US-20040147538-A1 | Fused heterocyclic compounds | AMGEN INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004043958-A1 | FUSED HETEROCYCLIC COMPOUNDS | AMGEN INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194826-A1 | Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same | CYP4F2, CYP1A2, CYP4B1 | CYP4F2 1/4885CYP4A11 5/4885NPSR1 1840/4885 |
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | CHRM2, NR3C2, NPSR1 | CYP4F2 557/4885CYP4A11 177/4885NPSR1 3/4885 |
| US-20080058365-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | CYP4F2 700/4885CYP4A11 1152/4885NPSR1 82/4885 |
| US-20040147538-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | CYP4F2 700/4885CYP4A11 1152/4885NPSR1 82/4885 |
| US-20050085508-A1 | Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | OPRM1, OPRD1, HRH4 | CYP4F2 508/4885CYP4A11 612/4885NPSR1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.